Joseph H. Antin, MD, Dana-Farber Cancer Institute
Advertisement
Articles by Joseph H. Antin, MD, Dana-Farber Cancer Institute
Advertisement
Latest Updated Articles
Risk Factors for Graft-vs-Host DiseasePublished: June 19th 2020 | Updated:
Special Transplant SituationsPublished: June 19th 2020 | Updated:
Members of the Transplant TeamPublished: June 19th 2020 | Updated:
Timing of Referral for TransplantPublished: June 19th 2020 | Updated:
Graft-vs-Host Disease Prophylaxis Clinical TrialsPublished: June 19th 2020 | Updated:
Shifting Paradigm in Treating Acute Graft-vs-Host DiseasePublished: June 19th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
3
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
4
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
5